Long-term safety of ONO-4538 in people with various cancers
Checks long-term safety of ONO-4538 in people with cancer continuing prior treatment.
Plain-language title generated from the registry record
Registry title: ONO-4538 Phase II Rollover Study (ONO-4538-98)
Key facts
- Where
- Kaohsiung City, New Taipei City, Tainan, Taipei, and Taoyuan, TaiwanSee the 8 sites
- Phase
- Phase 2
Where in Taiwan
- Kaohsiung CityKaohsiung City, TaiwanNo longer taking part
- Kaohsiung CityKaohsiung City, TaiwanNo longer taking part
- New Taipei CityNew Taipei City, TaiwanTaking people
- TainanTainan, TaiwanTaking people
- TainanTainan, TaiwanTaking people
- TaipeiTaipei, TaiwanTaking people
- TaipeiTaipei, TaiwanTaking people
- TaoyuanTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ono Pharmaceutical Co., Ltd.
- Trial code
- NCT04566380
- Record updated
- 14 October 2026
- Original description
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.Read full original descriptionShow less
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Inclusion: Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials; Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit.
Exclusion: Participant judged to be incapable of providing consent for reasons such as concurrent dementia; Participant judged by the investigator to be inappropriate as participants of this study.